How Your Body Processes an Experimental Cancer Drug
Part of Cancer clinical trials.
This is an early-stage study testing how a new cancer medication (zorifertinib) moves through and leaves a healthy male body. Researchers use a special radioactive marker to track the drug so they can understand how it works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy Chinese male, aged 18–45
- Your weight and body composition fall within a normal range (BMI 19–26, weight at least 50 kg)
- You have not taken any prescription drugs, over-the-counter medications, herbal supplements, or vitamins in the past 2 weeks
- You do not have a serious medical history (heart disease, digestive disorders, immune conditions, or cancer) and have not had major surgery in the past 6 months
- You have not smoked more than 5 cigarettes per day in the past 3 months, do not drink alcohol regularly, and have not used any recreational drugs in the past year
- You are willing to stay in the research facility, provide blood and urine samples regularly, and avoid alcohol, smoking, and caffeine during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tracks how well zorifertinib works as a first treatment for people with a specific type of advanced lung cancer that has spread to the brain or spinal cord lining. Participants may receive zorifertinib or another standard treatment, and researchers will monitor their response over time.
This Phase 1 study tests XZB-0004 in adults with solid cancers to check safety and how the body responds to the drug. It may help doctors learn whether this treatment could be useful for certain tumor types, including non-small cell lung cancer.
This study tests how a healthy male body absorbs, uses, and removes a new experimental medication. Researchers track the drug's path through your body using a special radioactive marker to understand how it works and ensure it's safe.
This trial tests a new oral drug (ZX-8177) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with standard options. The goal is to see if it is safe and helps control the disease.
This trial tests a new drug called ZG005 in people with advanced solid tumors that have not spread to the brain. It aims to see if the drug is safe and can help shrink tumors.
This trial tests a combination of zorifertinib (a targeted lung cancer drug) plus chemotherapy delivered directly into the fluid around your brain and spinal cord through a small surgical device. It's designed for patients with non-small cell lung cancer that has spread to the membrane covering the brain after previous EGFR-targeted treatments.
Hear when a new EGFR Mutant Advanced Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.